Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mutant EGFR-targeted peptide vaccine plus EGFR TKI in refractory EGFR-mutant advanced lung cancer
TCTR20240422007Phase 2Active, not recruiting
- Sponsor
- CU Cancer Immunotherapy Fund, Thailand Science Research and Innovation (Fundamental Fund)
- Start
- Feb 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in bronchial carcinoma, sponsored by CU Cancer Immunotherapy Fund, Thailand Science Research and Innovation (Fundamental Fund). Primary endpoints: Primary immunological response and Safety and tolerability. Started Feb 2024; status: active, not recruiting.
02
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on TCTR20240422007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240422007.